Biotech Values

[jellybean]

Agreed. Shoo-in is a bit stronger than I would state as only the company and the FDA see the entire data set and you never know what nasty detail could be lurking. Given von Eschenbaum's previous statements regarding cancer drugs (he thinks there need to be more treatment options), my best guess is that the drug will receive accelerated approval.

BTW, Feuerstein's subset analysis is based on fewer than 58 patients total. He also seemed to leave out the little detail that for HRPC patients increasing pain is correlated with progression.

thanks for the reference!